Skin-like condoms having active ingredients to enhance a male erection and a female arousal

ABSTRACT

A condom assembly includes at least one of a condom, patch or glove made of at least one of natural latex, synthetic latex or the mixture of natural latex and synthetic latex. The natural latex, synthetic latex or the mixture of natural latex and synthetic latex contain prodrugs of nitric oxide and/or other active ingredients.

PRIORITY OF INVENTION

This application claims priority from U.S. Provisional Application No.62/248,196, filed 29 Oct. 2015, which is hereby incorporated byreference in its entirety.

BACKGROUND

As a method of birth control, condoms have many advantages of low-cost,easy to use, and providing protection against numerous sexuallytransmitted infections (STIs). However, the drawbacks to more universaland consistent use of condoms are their tendencies to decrease pleasureand/or induce the loss of erection. The reason for these obstacles isthat condoms are made from hydrophobic materials, such as latex,polyurethane, and polyisoprene. These hydrophobic materials are excludedfrom the human physiological environment, such as the surface of theskin. Thus, currently used condoms always cause the foreign bodysensation to decrease pleasure and/or induce the loss of erection.

In addition, condoms are currently most often made from natural latex,which is derived from the sap of some plants. However, the use of latexcondoms may cause allergic symptoms in people with an allergy to latex.In some normal people, the development of a latex allergy may be causedby the repeated use of latex condoms. To reduce the level of theallergy, some chemical synthesized materials, such as polyurethane andpolyisoprene are used to make male condoms. A female condom was alsodeveloped, which is often made from nitrile. The condom made of naturallatex has high quality of elastic properties. It can be stretched inexcess of 800% before breaking and the tensile strength exceeds 30 MPa.A polyurethane condom has several better properties than latex condom:it does not have an odor; has a higher efficiency to transmit body heat;is less allergenic; has a longer storage life, and can be used withoil-based lubricants. However, a polyurethane condom has less elasticitythan a latex condom. It is more likely to lose their shape, bunch up,break or slip than latex. Similar to a polyurethane condom, a nitrilecondom has improved chemical resistance. However, it is less elasticthan a latex condom too. A polyisoprene condom has less tensile strengththan latex condom. However, it has the highest elongation beforebreaking (>1050%) and lower moduli, which result in increased softness.It also does not have an odor and has a higher efficiency to transmitbody heat. In addition, it does not include proteins that cause latexallergies.

To benefit the erection, several patents have described condoms coatedwith active ingredients on their surface. For example, U.S. Pat. No.4,829,991 describes a condom that coated with a vasodilator in itsinterior surface except at the closed and open end portions. Thevasodilator (such as a nitroglycerine) transdermal coating on thesurface of the condom contacts the skin of part of the shaft of thepenis, after it is fitted onto a penis. The friction between the condomand the penis breaks the surface tension of the transdermal vasodilatorcoating and results in the gradual development of an erection.

U.S. Pat. No. 6,840,244 also describes a condom that can be used todeliver erectogenic compounds. In this patent, an erectogenic compoundis coated on the interior surface of a condom in the closed end. Theerectogenic compound is applied as a finely-divided form or as a filmlayer by the use of a solvent carrier, which is subsequently evaporatedto leave the compound immobilised. In another way, the erectogeniccompound is applied on the condom as a component of a composition, whichis dispersed or dissolved in a gel carrier including a liquid medium anda thickening agent. The liquid medium is vegetable oil or apolyhydroxy-based medium. And the thickening agents include hectorite,jojoba oils, waxes or cellulose derivatives.

Int.'l Pat. Publication WO/2009/134767 describes a condom that affixes alow melt wax bead comprising an active ingredient on the interiorsurface of the condom in its tip. The bead comprises a polyethyleneglycol-based wax or a natural wax mixed with polyethylene glycol. Thewax softens in the range of 25-40° C. to substantially expose the activeingredients. Active ingredients include spermicides (e.g. nonoxynol-9),vasodilators (e.g. nitroglycerin, niacin, and sildenafil citrate) andmale desensitizing agents (e.g. benzocaine). The exterior surface of thecondom is free of the active ingredient.

It is an easily manipulated method to coat active ingredients on thesurface of a condom described as above patents. However, the coatingmaterials such as polyethylene glycol, jojoba oils, waxes or celluloseare very sticky, which are not pleasurable to users. In addition, thesesmooth adjuvant materials make condoms easily slipping off.

Recently, Int.'l Pat. Publication WO/2015/068174 describes a condom madeof polymers mixed with graphene and its derivatives. The graphene andits derivatives are loaded with or without active ingredients touniformly disperse into polymers. The mixed polymer is used to preparecondoms by dip casting methods. The pharmaceutical active ingredients inthe nanocomposites of graphene and its derivatives are prepared forrelease during intercourse to increase the sexual pleasure. The condomprepared in this patent has higher mechanical strength and heattransfer. However, the active ingredients are trapped in thenanoparticles of graphene and its derivatives. Thus, the release rateand efficiency of the active ingredients are limit. In addition, theouter surface of the graphene nanoparticle is hydrophobic, which is notobservably change the polarity of the surface of condom.

SUMMARY

A skin-like condom assembly is described herein including at least oneof a condom, patch or glove made of at least one of natural latex,synthetic latex or the mixture of natural latex and synthetic latex, andnatural latex, synthetic latex or the mixture of natural latex andsynthetic latex contains prodrugs of nitric oxide and/or other activeingredients.

In one or more options, the skin-like condom, patch or glove is alsodescribed as ‘skin mimic condom, patch or glove’, ‘skinny condom, patchor glove’ or similar description.

In one or more options, the synthetic latex includes one or more ofinclude polyurethane, polyisoprene, or nitrile latex.

A method is described herein including a method to prepare a condom,patch or glove made of natural latex or synthetic latex containingactive ingredients in the whole entity or outside surface(s).

A compound is described herein including a compound having a prodrug ofnitric oxide.

In a further option, the usage of prodrugs of nitric oxide to enhance amale erection and a female arousal, is described herein.

A condom assembly is described herein, including at least one of acondom, patch or glove used to deliver one or more other activeingredients selected from the group consisting of arginine, vasodilatorsor related compounds, including the nitrates, ergot alkaloids, long andshort acting alpha-adrenoceptor blockers, anti-hypertenives, theprostaglandins and phosphodiesterase inhibitors.

The above active agents may be used either alone or in combination.

In one or more options, the condom, patch or glove may include or notinclude a hydrophilic adjuvant, such as lecithin and its analogues,polysaccharide analogues, or proteins.

In one or more embodiments, a condom, patch or glove is made of naturallatex, synthetic latex or the mixture of natural latex and syntheticlatex containing extra protein(s).

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s) or phospholipid(s).

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s) and/or polysaccharide.

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s), phospholipid(s), andpolysaccharide(s).

In one or more embodiments, synthetic latexes include polyurethane,polyisoprene or nitrile latex.

In one or more embodiments, proteins are derivable from caseinate (Na,K, NH₄, Mg, Ca, Zn), extraction of milk, soybeans, peanuts, corn andother natural objects.

In one or more embodiments, phospholipids include lecithin, phosphatidicacid, phosphatidylethanolamine, phosphatidylserine,phosphatidylinositol, phosphatidylinositol phosphate, ceramidephosphorylcholine, ceramide phosphorylethanolamine, or ceramidephosphoryllipid.

In one or more embodiments, polysaccharides include starch, glycogen,cellulose, chitin, callose, laminarin, chrysolaminarin, xylan,arabinoxylan, mannan, fucoidan and galactomannan.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates compound 1 and its potential modified sites inaccordance with one or more embodiments.

FIG. 2I illustrates a cross-section of a condom layer of formulation Ain accordance with one or more embodiments.

FIG. 2II illustrates a cross-section of a condom layer of formulation Aand formulation B in accordance with one or more embodiments.

FIG. 2III illustrates a cross-section of a condom layer of formulation Aand formulation B in accordance with one or more embodiments.

FIG. 2IV illustrates a cross-section of a condom layer of formulation Aand formulation B in accordance with one or more embodiments.

FIG. 3 illustrates a chart showing the time-dependent release ofD-glucosylated PROLI/NO from condom I.

FIG. 4 illustrates formulations for polyisoprene latex.

FIG. 5 illustrates a table showing properties of condom prepared usingformulations of A and B.

DETAILED DESCRIPTION

A skin-like condom containing pharmaceutical active ingredients thatuniformly distribute on the surface of latex particles is describedherein. The term condom and skin-like condom includes a condom, patch,or glove.

Condoms are prepared using polyisoprene latex containing prodrugs ofnitric oxide. The prodrugs of nitric oxide will be released from thesecondoms; transported into smooth muscle cells; decomposed to nitricoxide. The nitric oxide activates the erection and female arousal.

A condom assembly is described herein, including at least one of acondom, patch or glove used to deliver other active ingredients selectedfrom the group consisting of arginine, vasodilators or relatedcompounds, including the nitrates, ergot alkaloids, long and shortacting alpha-adrenoceptor blockers, anti-hypertenives, theprostaglandins or phosphodiesterase inhibitors. The above active agentsmay be used either alone or in combination.

In one or more options, the condom, patch or glove may include or notinclude a hydrophilic adjuvant, such as lecithin and its analogues,polysaccharide analogues, or proteins.

In one or more embodiments, a condom, patch or glove is made of naturallatex, synthetic latex or the mixture of natural latex and syntheticlatex containing extra protein(s).

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s) and phospholipid(s).

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s) and polysaccharide.

In one or more embodiments, a condom, patch or glove is made of naturallatex or synthetic latex containing protein(s), phospholipid(s), andpolysaccharide(s).

In one or more embodiments, synthetic latexes include polyurethane,polyisoprene and nitrile latex.

In one or more embodiments, proteins are derivable from caseinate (Na,K, NH₄, Mg, Ca, Zn), extraction of milk, soybeans, peanuts, corn andother natural objects.

In one or more embodiments, phospholipids include lecithin, phosphatidicacid, phosphatidylethanolamine, phosphatidylserine,phosphatidylinositol, phosphatidylinositol phosphate, ceramidephosphorylcholine, ceramide phosphorylethanolamine, or ceramidephosphoryllipid.

In one or more embodiments, polysaccharides include starch, glycogen,cellulose, chitin, callose, laminarin, chrysolaminarin, xylan,arabinoxylan, mannan, fucoidan or galactomannan.

The active ingredient has higher hydrophilic property than latexparticle. Thus the novel condom containing pharmaceutical activeingredients on the surface of latex particles has increased polarity andelectroconductivity. The condom itself provides increased pleasure tousers since its surface is friendly to human skin. The active ingredientreleases out promptly and continuously, which provide constantenhancement for the erection of penis. Some active ingredients (e.g.nitric oxide derivatives) can also increase female arousal, whichprovide increased pleasure for both partners. In addition, the activeingredient(s) can increase the mechanical strength and heat transferability of the condom. The novel condoms containing pharmaceuticalactive ingredients on the surface of latex particles are prepared toenhance a male erection and a female arousal, increase pleasure for bothpartners, prevent pregnancy and sexually transmitted diseases.

The present invention also provides a novel prodrug of nitric oxide,D-glucosylated PROLI/NO (1, FIG. 1). This prodrug and its derivativesmay arouse and enhance the erection for male, and may also arouse andenhance sexual excitement for female.

The disadvantage of currently used condoms is the decreasing pleasureand/or inducing the loss of erection, since they were made ofhydrophobic materials that are excluded from the human physiologicalenvironment, such as the surface of the skin. In this invention apharmaceutical active ingredient is uniformly distribute on the surfaceof latex particles to increase the polarity and the mechanical strengthof condom, which is friendly to human skin to increase pleasure for bothpartners. In addition, the active ingredient releases out from thecondom, provides enhancement for the erection of penis and femalearousal, results in more pleasure to both partners.

One embodiment provides a condom (FIG. 2I) made of polyisoprene latexcomposition comprising D-glucosylated PROLI/NO (1), which is a prodrugof nitric oxide. The formulation (A) of this polyisoprene latex contains1.0 phr of D-glucosylated PROLI/NO and small amount of hydrophilicadjuvant. As a control, another formulation (B) just containspolyisoprene latex without D-glucosylated PROLI/NO and hydrophilicadjuvant. The condom made from formulation A has a much higherhydrophily and litter higher mechanical strength than that offormulation B. The contact angle (θ) of 5 μL water on the surface ofpolyisoprene condom made from formulation A is 18 degrees, and theelongation is 1400%. Comparatively, the contact angle (θ) of 5 μL wateron the surface of polyisoprene condom made from formulation B is 82degrees, and its elongation is 1050%.

The second embodiment provides a condom (FIG. 2II) making up offormulation (A) of latex on the internal side and formulation (B) on theexternal side of condom. The third embodiment provides a condom (FIG.2III) making up of formulation (A) of latex on the external side andformulation (B) on the internal side of condom.

The fourth embodiment provides a condom (FIG. 2IV) making up offormulation (A) of latex on the both sides and formulation (B) in themiddle layer of condom.

The latex in this invention may use natural latex, synthetic latex orthe mixture of natural latex and synthetic latex. The synthetic latexesinclude polyurethane, polyisoprene and nitrile latex. The forms of thelatex to delivery pharmaceutical active ingredient(s) include condom,patch or glove.

The pharmaceutical active ingredients for enhancing a male erection anda female arousal include but not limit to prodrugs of nitric oxide, suchas glucosylated PROLI/NO (1) and its analogues: R1 includes but notlimit to hydrogen (H), hydroxymethyl (—CH₂OH), aminomethyl (—CH₂NH₂) andits derivatives, carboxyl (—COOH) and its derivatives, carboxamide(—CONH₂) and its derivatives. R2 and R3 may be two separate aliphatichydrocarbon chains or aromatic hydrocarbons chains; or forms a ringwhich includes 3 to 15 atoms. R4 includes but not limit to aliphatichydrocarbon, aromatic hydrocarbons, galactose, glucose, mannose,N-acetylglucosamine and their O-acetyl derivatives.

The condom, patch or glove may be used to delivery other kinds of activeingredients, such as arginine, vasodilators or related compounds,including the nitrates, ergot alkaloids, long and short actingalpha-adrenoceptor blockers, anti-hypertenives, the prostaglandins andphosphodiesterase inhibitors

Suitable nitrates include but not limit to amyl nitrate, erythrityltetranitrate, isosorbide dinitrate, nitro-glycerine, sodiumnitroprusside, linsidomine chlorydrate (“SIN-1”), molsidomine,S-nitroso-N-acetyl-d,l-penicillamine (“SNAP”), S-nitroso-N-glutathione(“SNO-GLU”), S-nitroso-N-cysteine, and diazenium diolates (“NONOates”).

Useful prostaglandins include but not limit to PGA₁, PGB₁, PGE₀, PGE₁,PGF₁alpha, 19-hydroxy-PGA₁, 19-hydroxy-PGB₁, PGA₂, PGB₂, PGE2,19-hydroxy-PGA₂, 19-hydroxy-PGB₂, PGE₃, PGF₃alpha, carboprosttromethamine, dinoprostone, dinoprost tromethamine, gemeprost,lipoprost, metenoprost, sulprostone and tiaprost.

Suitable alpha-adrenoceptor blockers include but not limit to alfuzosin,dibenamine, doxazosin, indoramin, phenoxybenzamine, phentolamine,prazosin, tamsulosin, terazosin, trimazosin, and tolazoline.

Useful ergot alkaloids include but not limit to acetergamine,bromerguride, brazergoline, cianergoline, disulergine, delorgotrile,ergonovine maleate, etisulergine, ergotamine tartrate, lergotrile,lysergide, metergoline, metergotamine, mesulergine, nicergoline,pergolide, proterguride, propisergide and terguride.

Suitable type III phosphodiesterase inhibitors include but not limit toamirinone, anergrelide, bemoradan, cilostamide, cilostazol, enoximone,imazodan, indolidan, isomazole, 5-methyl-imazodan, lixazinone,milrinone, pimobendan, piroximone, siguazodan, trequinsin, vesnarinone,ICI1118233, SKF-94120 and SKF-95654.

Usable type IV phosphodiesterase inhibitors include but not limit toetazolate, nitraquazone and nitraquazone derivatives, rolipram androlipram derivatives, xanthine and xanthine derivatives.

Suitable type V phospodiesterase inhibitors include but not limit tosildenafil, tadalafil, vardenafil, and zaprinast.

Other compounds include IBMX, papaverine, pentoxifylline, theophylline,cyclandelate, chloromazine, haloperidol, isoxsuprine, nimodipine,pinacidil, and trazodone, as well as anti-hyertensive agents includingminoxidil, hydralazine and diazoxide.

The above active agents may be used either alone or in combination.

The condom, patch or glove may include or not include a hydrophilicadjuvant, such as lecithin and its analogues, polysaccharide analogues,and proteins.

The active ingredient releases out promptly and continuously from thecondoms. In a release assay, around 55% of D-glucosylated PROLI/NO isreleased into water from condom in 5 min (FIG. 3). And 81% of thisprodrug is released out in 30 min. The continuous release of activeingredient provides constant enhancement of pleasure for both partners.

EXAMPLES Example 1

The tetra-acetyl-D-glucosylated PROLI/NO was prepared as reportedprocedure. To a solution of tetra-acetyl-D-glucosylated PROLI/NO (316mg, 0.625 mmol) in 15 mL of anhydrous methanol was added 25% NaOMe inmethanol (20 μL, 0.09 mmol). The reaction mixture was stirred at rt for2 h. The crude product was purified by flash column chromatography (9:1CH₂Cl₂/MeOH eluent) to give 1 (125 mg, 62%) as a white solid. H NMR (400MHz, CD₃OD) δ: 1.28-2.06 (m, 4H), 3.28-3.46 (m, 4H), 3.50-3.72 (m, 5H),3.83 (d, J=1 Hz, 1H), 4.06-4.09 (m, 1H), 4.83 (s, 5H), 4.96 (d, J=8 Hz,1H); ¹³C NMR (CD₃OD) δ: 22.3, 26.2, 52.2, 61.0, 63.1, 69.6, 71.7, 76.4,77.1, 103.3.

14.12; MALDI: m/z=346 for (M+Na)⁺

Example 2

The formulation (A) of polyisoprene latex is prepared by mixing 100 phrof compounded Cariflex IR0401 latex (Kraton Polymers U.S. LLC) with 1.0phr of D-glucosylated PROLI/NO. The compounded latex is stirred at roomtemperature for 2-8 h and centrifuged for 5 min. Then smooth glassformers are dipped in the latex suspension for 1 min and dried at 60° C.for 5 min.

The dipping and drying procedures are repeated three to four times.Finally, the condoms are cured at 130° C. for 15 min.

Example 3

The formulation (B) of polyisoprene latex is prepared by mixing thecompounded Cariflex IR0401 latex (Kraton Polymers U.S. LLC) withoutD-glucosylated PROLI/NO and hydrophilic adjuvant. The compounded latexis stirred at room temperature for 2-8 h and centrifuged for 5 min.

Then smooth glass formers are dipped in the formulation (A) of latexsuspension for 1 min and dried at 60° C. for 5 min. This procedure isrepeated one time. Then the formers coated with the formulation (A) oflatex are dipped in the formulation (B) of latex suspension for 1 minand dried at 60° C. for 5 min. The latter dipping and drying proceduresare repeated one time. Finally, the condoms are cured at 130° C. for 15min.

Example 4

The smooth glass formers are dipped in the formulation (B) of latexsuspension for 1 min and dried at 60° C. for 5 min. This procedure isrepeated one time. Then the formers coated with the formulation (B) oflatex are dipped in the formulation (A) of latex suspension for 1 minand dried at 60° C. for 5 min. The latter dipping and drying proceduresare repeated one time. Finally, the condoms are cured at 130° C. for 15min.

Example 5

The smooth glass formers are dipped in the formulation (A) of latexsuspension for 1 min and dried at 60° C. for 5 min. Then the formerscoated with the formulation (A) of latex are dipped in the formulation(B) of latex suspension for 1 min and dried at 60° C. for 5 min. Thelatter dipping and drying procedures are repeated one time. Then theformers are dipped again in the formulation (A) of latex suspension for1 min and dried at 60° C. for 5 min. Finally, the condoms are cured at130° C. for 15 min.

Example 6

One condom containing 7 mg of D-glucosylated PROLI/NO is suspended in 20mL of pure water. A 100-μL of sample is taken out at 2 min, 5 min, 10min, 15 min, 20 min, 25 min and 30 min. The UV absorption is measured at255 nm. As a control, a condom without the D-glucosylated PROLI/NO isalso treated as the same way. The release amount is calculated based onthe UV absorption of pure D-glucosylated PROLI/NO.

Example 7

In one or more embodiments, a skin-like condom is described herein,which mimics the membrane of living cells to increase pleasure. Thehuman cell membrane is a biological membrane that surrounds thecytoplasm of living cells. It involves in a variety of cellularprocesses such as ion conductivity, cell adhesion and cellcommunication. Cell membrane consists of a lipid bilayer with embeddedproteins. The glycosylation of the surface of embedded proteins increasethe hydrophily of the membrane. In this study, we added a D-glucosylatedPROLI/NO and several hydrophilic adjuvants into

the polyisoprene latex and used this mixture to prepare condoms. Thehydrophilic compounds located at the surface

of the polyisoprene condom to mimic the surface of cell membrane forhigher hydrophily and increased sensation.

Condoms have been prepared with two different formulations ofpolyisoprene latex (FIG. 4). Both polyisoprene latex formulationscontain Cariflex IR0401 latex (Kraton Polymers U.S LLC); bridging agent(sulfur); activator (ZnO); accelerators (ZDEC and DPG); and anti-oxidant(BHT). Besides these uniform agents, formulation A containsD-glucosylated PROLI/NO, sodium caseinate, lecithin and sodiumcarboxymethyl cellulose; formulation B only contains a sodium caseinate.

The contact angle (θ) of 5 μL water on the surface of polyisoprenecondom made from formulation A is 18 degrees (FIG. 5), and theelongation is 1400%. The active ingredients in latex dramaticallyincreases the hydrophily and slightly increases the flexibility of thecondom. The contact angle (θ) of 5 μL water on the surface ofpolyisoprene condom made from formulation B is 82 degrees, and theelongation is 1050%.

In summary, we prepared skin-like condoms using two formulations ofpolyisoprene latex to mimic the membrane of living cells. These condomshave increased hydrophily and flexibility compared to condoms that madefrom natural latex. The condoms prepared in this study will increasepleasure and decrease the rate of latex allergies.

The present invention provides a novel condom containing pharmaceuticalactive ingredients that uniformly distribute on the surface of latexparticles. The active ingredient has higher hydrophilic property thanlatex particle. Thus the novel condom containing pharmaceutical activeingredients on the surface of latex particles has increased polarity andelectroconductivity. The condom itself provides increased pleasure tousers since its surface is friendly to human skin. The active ingredientreleases out promptly and continuously, which provide constantenhancement for the erection of penis. Some active ingredients (e.g.nitric oxide derivatives) can also increase female arousal, whichprovide increased pleasure for both partners. In addition, the activeingredient(s) can increase the mechanical strength and heat transferability of the condom. The novel condoms containing pharmaceuticalactive ingredients on the surface of latex particles are prepared toenhance a male erection and, a female arousal, increase pleasure forboth partners, prevent pregnancy and sexually transmitted diseases. Thepresent invention also provides a novel prodrug of nitric oxide,D-glucosylated PROLI/NO. This prodrug and its derivatives may arouse andenhance the erection for male, and may also arouse and enhance sexualexcitement for female.

The use of the terms “a” and “an” and “the” and similar referents in thecontext of describing the invention are to be construed to cover boththe singular and the plural, unless otherwise indicated herein orclearly contradicted by context. The terms “comprising,” “having,”“including,” and “containing” are to be construed as open-ended terms(i.e., meaning “including, but not limited to”) unless otherwise noted.Recitation of ranges of values herein are merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range, unless otherwise indicated herein, and eachseparate value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in any suitable order unless otherwise indicated herein orotherwise clearly contradicted by context. The use of any and allexamples, or exemplary language (e.g., “such as”) provided herein, isintended merely to better illuminate the invention and does not pose alimitation on the scope of the invention unless otherwise claimed. Nolanguage in the specification should be construed as indicating anynon-claimed element as essential to the practice of the invention.

Embodiments of this invention are described herein, including the bestmode known to the inventors for carrying out the invention. Variationsof those embodiments may become apparent to those of ordinary skill inthe art upon reading the foregoing description. The inventors expectskilled artisans to employ such variations as appropriate, and theinventors intend for the invention to be practiced otherwise than asspecifically described herein. Accordingly, this invention includes allmodifications and equivalents of the subject matter recited in theclaims appended hereto as permitted by applicable law. Moreover, anycombination of the above-described elements in all possible variationsthereof is encompassed by the invention unless otherwise indicatedherein or otherwise clearly contradicted by context.

The invention claimed is:
 1. A condom assembly comprising: at least oneof a condom made of at least one of a natural latex, a synthetic latexor a mixture of the natural latex and the synthetic latex; and the atleast one of the natural latex, the synthetic latex or the mixture ofthe natural latex and the synthetic latex containing a compound ofFormula 1


2. The condom assembly as recited in claim 1, wherein the syntheticlatex, the mixture of the natural latex and the synthetic latex, thesynthetic latex containing the compound of Formula 1, or the mixture ofthe natural latex and the synthetic latex containing the compound ofFormula 1, each comprises polyurethane, polyisoprene, or nitrile latex.3. The condom assembly as recited in claim 1, wherein the condomcomprises a hydrophilic adjuvant.
 4. The condom assembly as recited inclaim 1, wherein the condom further comprises one or more proteins. 5.The condom assembly as recited in claim 1, wherein the condom comprisesone or more proteins and one or more phospholipids.
 6. The condomassembly as recited in claim 1, wherein the condom comprises one or moreproteins and one or more polysaccharides.
 7. The condom assembly asrecited in claim 1, wherein the condom comprises one or more proteins,one or more phospholipids, and one or more polysaccharides.
 8. Thecondom assembly as recited in claim 4, wherein the one or more proteinsare derived from caseinate, soybeans, peanuts, or corn.
 9. The condomassembly as recited in claim 5, wherein the one or more phospholipidscomprise lecithin, phosphatidic acid, phosphatidylethanolamine,phosphatidylserine, phosphatidylinositol, phosphatidylinositolphosphate, ceramide phosphorylcholine, ceramide phosphorylethanolamine,or ceramide phosphoryllipid.
 10. The condom assembly as recited in claim6, wherein the one or more polysaccharides include starch, glycogen,cellulose, chitin, callose, laminarin, chrysolaminarin, xylan,arabinoxylan, mannan, fucoidan, or galactomannan.